The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
 
Dan Feng
No Relationships to Disclose
 
Fionnuala Crowley
No Relationships to Disclose
 
Olivia Hapanowicz
Employment - Mount Sinai Hospital; Mount Sinai Hospital; Mount Sinai Hospital
 
Nicholas Venturini
No Relationships to Disclose
 
Natalie Lucas
Employment - Mount Sinai University Medical Center and School of Medicine
 
Kathy Wu
No Relationships to Disclose
 
Jessica Wilk
No Relationships to Disclose
 
Norah Sadek
No Relationships to Disclose
 
Pauline Hamon
No Relationships to Disclose
 
Clotilde Hennequin
No Relationships to Disclose
 
Varun Devraj
No Relationships to Disclose
 
Pradeep Thanigaimani
Employment - Regeneron
 
Thomas Uldrick
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - As an employee of Fred Hutchinson Cancer Center, I am named on a US Provisional Application No 63/337,8814, KSHV Oncoprotein antigens and epitopes for expanding KSHV-antigen specific T cells. (Inst); As an employee of Regeneron Pharmaceuticals, I am named on a US Patent 20230312718, "Methods for treating recurrent ovarian cancer with bispecific MUC16xCD3 antibodies alone or in combination with anti-PD1 antibodies" (Inst); As an employee of Regeneron Pharmaceuticals, I am named on a US Patent Application 63/608,922, "Methods of Treating Endometrial Cancer with Bispecific anti-MUC16 anti-CD3 antibodies alone and in combination with anti-PD1 antibodies" (Inst); As an employee of the U.S. Government, I have provisional patent application regarding methods for the treatment of Kaposi’s sarcoma and KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers (Inst)
(OPTIONAL) Uncompensated Relationships - Fred Hutchinson Cancer Research Center
 
Elizabeth Miller
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - involved in patents through employment at Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Deborah Doroshow
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Atheneum; Boehringer Ingelheim; Dedham Group; G1 Therapeutics; MJH Life Sciences; Sanofi; Sonata Therapeutics; Summit Therapeutics; Takeda
Travel, Accommodations, Expenses - Boehringer Ingelheim; MJH Life Sciences
Other Relationship - Bristol Myers Squibb Foundation; Conquer Cancer Foundation
 
Parissa Tabrizian
No Relationships to Disclose
 
Myron Schwartz
No Relationships to Disclose
 
Miriam Merad
No Relationships to Disclose
 
Thomas Marron
Consulting or Advisory Role - Abbvie; Arrowhead Pharmaceuticals; Astellas Pharma; AstraZeneca; Avammune; EMD Serono; Geneos; Merck; Regeneron; Replimune; Replimune; Storm Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
Travel, Accommodations, Expenses - Abbvie; Genentech